Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 2Lung Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Neoplasm Metastasis 1HRD Cancer 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Gemcitabine 26Specimen Handling 20130-nm albumin-bound paclitaxel 18Magnetic Resonance Spectroscopy 13Irinotecan 13Biopsy 12Fluorouracil 11Leucovorin 10Oxaliplatin 9Cyclophosphamide 8pembrolizumab 7fludarabine 7Albumin-Bound Paclitaxel 7Cisplatin 6Cetuximab 6Nivolumab 5durvalumab 4Taxes 4Radiosurgery 4Pemetrexed 4Capecitabine 4zimberelimab 3trastuzumab deruxtecan 3olaparib 3irinotecan sucrosofate 3dehydroftorafur 3aldesleukin 3Radiotherapy 3Immunoglobulin G 3Exercise 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × berzosertib × 30 days × Clear all
NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
66 enrolled
GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡